IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v44y2021i9d10.1007_s40264-021-01091-x.html
   My bibliography  Save this article

Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020

Author

Listed:
  • Elena Rocca

    (Uppsala Monitoring Centre
    Norwegian University of Life Sciences)

  • Oskar Gauffin

    (Uppsala Monitoring Centre)

  • Ruth Savage

    (Uppsala Monitoring Centre
    University of Otago
    University of Otago)

  • Sara Hedfors Vidlin

    (Uppsala Monitoring Centre)

  • Birgitta Grundmark

    (Uppsala Monitoring Centre)

Abstract

Introduction The safety profile of remdesivir, conditionally approved for COVID-19, was limited at its 2020 introduction. Adverse drug reactions (ADRs) for medicines are collected in VigiBase, the WHO Global Database of Individual Case Safety Reports (ICSRs). Objective This study aimed to provide a descriptive analysis of COVID-19 ICSR data focusing on remdesivir, including a disproportionality analysis (DA) of ADRs. Methods A dedicated algorithm enabled retrieval of all COVID-19 treatment-specific ICSRs. A severity algorithm based on co-reported medicines and symptoms enabled selection of tocilizumab with its well established safety profile as comparator for remdesivir. Descriptive statistics were used for general ICSR demographics for all COVID-19-specific medicines, remdesivir and tocilizumab individually and furthermore to present treatment patterns of medicines co-reported with remdesivir. A COVID-19 indication-focused DA was deployed to minimize confounding from underlying polysymptomatic disease. Results 14,574 COVID-19-related ICSRs were entered into VigiBase during 2020. Remdesivir was the most common medicine reported. Of 4944 remdesivir ICSRs, where tocilizumab was not co-reported, 93% described remdesivir as the sole suspect medicine. Sixty percent of ICSRs concerned males, median age was 63 years and the majority originated from the Americas (72%). In 1089 (21%) of remdesivir ICSRs, data indicated severe/critical disease. Co-reported medicines peaked during the first 3 days of remdesivir treatment. The DA for the established tocilizumab and the new remdesivir were mainly in line with the safety profiles for both medicines but suggested new safety concerns. The most reported ADRs for remdesivir represented liver dysfunction, kidney injury, death and bradycardia. Conclusion Global COVID-19-related ADR reporting proved useful in providing information on ADRs as well as on treatment patterns in this patient group. Indication-focused disproportionality analysis, together with the use of a comparator with a known safety profile, proved effective in identifying known safety information and suggested new safety concerns for remdesivir.

Suggested Citation

  • Elena Rocca & Oskar Gauffin & Ruth Savage & Sara Hedfors Vidlin & Birgitta Grundmark, 2021. "Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020," Drug Safety, Springer, vol. 44(9), pages 987-998, September.
    • Handle: RePEc:spr:drugsa:v:44:y:2021:i:9:d:10.1007_s40264-021-01091-x
    DOI: 10.1007/s40264-021-01091-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-021-01091-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-021-01091-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Devon E McMahon & Gregory A Peters & Louise C Ivers & Esther E Freeman, 2020. "Global resource shortages during COVID-19: Bad news for low-income countries," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 14(7), pages 1-3, July.
    2. Alem Zekarias & Sarah Watson & Sara Hedfors Vidlin & Birgitta Grundmark, 2020. "Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports," Drug Safety, Springer, vol. 43(12), pages 1309-1314, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Amm Quamruzzaman, 2020. "Exploring the Impact of Medical Brain Drain on Child Health in 188 Countries over 2000–2015," Societies, MDPI, vol. 10(4), pages 1-16, September.
    2. Charles Crabtree & John B. Holbein & J. Quin Monson, 2022. "Patient traits shape health-care stakeholders’ choices on how to best allocate life-saving care," Nature Human Behaviour, Nature, vol. 6(2), pages 244-257, February.
    3. Orlando, Beatrice & Tortora, Debora & Pezzi, Alberto & Bitbol-Saba, Nathalie, 2022. "The disruption of the international supply chain: Firm resilience and knowledge preparedness to tackle the COVID-19 outbreak," Journal of International Management, Elsevier, vol. 28(1).
    4. Jane K L Teh & David A Bradley & Jack Bee Chook & Kee Huong Lai & Woo Teck Ang & Kok Lay Teo & Suat-Cheng Peh, 2021. "Multivariate visualization of the global COVID-19 pandemic: A comparison of 161 countries," PLOS ONE, Public Library of Science, vol. 16(5), pages 1-11, May.
    5. Katinka den Nijs & Jose Edivaldo & Bas D. L. Châtel & Jeroen F. Uleman & Marcel Olde Rikkert & Heiman Wertheim & Rick Quax, 2022. "A Global Sharing Mechanism of Resources: Modeling a Crucial Step in the Fight against Pandemics," IJERPH, MDPI, vol. 19(10), pages 1-17, May.
    6. Okeke, Edward N., 2022. "Playing defense? Health care in the era of Covid," Journal of Health Economics, Elsevier, vol. 85(C).
    7. Edward G. Anderson & David R. Keith & Jose Lopez, 2023. "Opportunities for system dynamics research in operations management for public policy," Production and Operations Management, Production and Operations Management Society, vol. 32(6), pages 1895-1920, June.
    8. Koppiahraj Karuppiah & Bathrinath Sankaranarayanan & Syed Mithun Ali & Sanjoy Kumar Paul, 2021. "Key Challenges to Sustainable Humanitarian Supply Chains: Lessons from the COVID-19 Pandemic," Sustainability, MDPI, vol. 13(11), pages 1-20, May.
    9. Catia Marzolini & Felix Stader & Anne Leuppi-Taegtmeyer & Marcel Stoeckle & Manuel Battegay & Parham Sendi, 2021. "Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19," Drug Safety, Springer, vol. 44(2), pages 255-257, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:44:y:2021:i:9:d:10.1007_s40264-021-01091-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.